Here we describe ARB-1740, an improved second-generation RNA interference therapeutic for chronic Hepatitis B infection (CHB).
• CHB is a global health challenge with 240 million individuals at risk of serious complications such as liver cirrhosis and cancer
• HBV proteins such as surface antigen (HBsAg) are associated with immune impairment, leading to persistent infection and posing a challenge for the development of a functional cure
• ARB-1740 is 3 siRNAs encapsulated in lipid nanoparticles (LNP); the drug utilizes a gene silencing mechanism to destroy HBV RNAs enabling suppression of all HBV antigens and promoting host immune recognition and viral control